The effect of calcium with or without calcitriol supplementation on renal function in patients with hypovitaminosis D and chronic kidney disease

Nephro-Urology Monthly

Volumn 6, Issue 1, 2014, Pages

  Mustafar, Ruslinda ^a   Mohd, Rozita ^a   Ahmad Miswan, Norazinizah ^a   Cader, Rizna ^a   Gafor, Halim A ^a   Mohamad, Marlyn ^a   Shah, Shamsul Azhar ^a   Kamaruddin, Nor Azmi ^a   Chiew Tong, Norella Kong ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Calcitriol; Chronic; Renal insufficiency; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CREATININE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; KIDNEY FUNCTION; MALE; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY;

EID: 84902360126     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: 10.5812/numonthly.13381     Document Type: Article

References (36)

1. Baeke F, Etten EV, Overbergh L, Mathieu C. Vitamin D3 and the immune system: maintaining the balance in health and disease. Nutr Res Rev. 2007;20(1):106-18.
2. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362-71.
3. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315-21.
4. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):1144-51.
5. Hollis BW, Wagner CL, Drezner MK, Binkley NC. Circulating vitamin D3 and 25-hydroxyvitamin D in humans: An important tool to define adequate nutritional vitamin D status. J Steroid Biochem Mol Biol. 2007;103(3-5):631-4.
6. Schneider AE Epstein S. Drug and hormone effects on vitamin D metabolism. 2nd ed. Amsterdam, The Netherland: Elsevier; pp. 1253-1291.
7. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88-95.
8. Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant. 2010;25(9):2850-65.
9. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKDMineral and Bone Disorder (CKD-MBD). Am J Kidney Dis;55(5):773-99.
10. Malluche HH, Kubodera N. [Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease]. Clin Calcium. 2002;12(6):724-9.
11. Bikle DD. Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep. 2009;7(2):58-63.
12. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol. 2009;5(12):691-700.
13. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730-7.
14. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50(1):59-68.
15. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008;14(1):10-7.
16. Tareen N, Martins D, Zadshir A, Pan D, Norris KC. The impact of routine vitamin supplementation on serum levels of 25 (OH) D3 among the general adult population and patients with chronic kidney disease. Ethn Dis. 2005;15(4 Suppl 5):S5-102.
17. Ranbaxy Pharmaceuticals Inc. Product Insert-Calcitriol. August, 2011.
18. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol. 2007;18(6):1796-806.
19. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-38.
20. Qunibi WY, Abdellatif A, Sankar S, Hamdan Z, Lin FY, Ingle J, et al. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? Clin Nephrol. 2010;73(4):276-85.
21. Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS. Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab. 1984;59(6):1063-9.
22. Pesenson A, Maski M, Kaufman J. Prevalence of 25-OH vitamin D (25-OH) defi{ligature}ciency in patients with chronic kidney disease (CKD) and effects of correction following KDOQI guidelines. American Society of Nephrology Renal Week, San Diego 14-19 November CA, USA. 2006.
23. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation. 2005;79(1):108-15.
24. Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AW. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet. 1976;1(7968):1044-7.
25. Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet. 1978;2(8092 Pt 1):700-3.
26. Coen G, Mazzaferro S, Bonucci E, Ballanti P, Massimetti C, Donato G, et al. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte Metab. 1986;12(5-6):375-82.
27. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67(5):929-36.
28. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 1989;35(2):661-9.
29. Lim YN, Lim TO, Lee DG, Wong HS, Ong LM, Shaariah W, et al. A report of the Malaysian dialysis registry of the National Renal Registry, Malaysia. Med J Malaysia. 2008;63(Suppl C):5-8.
30. Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, et al. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone. 2009;45(5):949-55.
31. Elder GJ, Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res. 2006;21(11):1778-84.
32. Yaturu S, Davis J. Prevalence of Decreased Vitamin D Levels is High among Veterans with Diabetes and/or CKD. ISRN Endocrinol. 2011;2011:109458.
33. Alshayeb HM, Wall BM, Showkat A, Mangold T, Quarles LD. Chronic Kidney Disease and Diabetes Mellitus Predict Resistance to Vitamin D Replacement Therapy. Am J Med Sci. 2013; 345(4):314-20.
34. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008;73(2):163-71.
35. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998;24(6):381-8.
36. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249-55.